Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity.
Sci Immunol
; 4(38)2019 08 09.
Article
in En
| MEDLINE
| ID: mdl-31399492
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Adaptive Immunity
/
ErbB Receptors
/
Immunity, Innate
/
Lung Neoplasms
/
Antineoplastic Agents
Limits:
Animals
Language:
En
Journal:
Sci Immunol
Year:
2019
Document type:
Article
Affiliation country:
Country of publication: